• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

胶质母细胞瘤中肿瘤浸润免疫细胞的分布

Distribution of tumor-infiltrating immune cells in glioblastoma.

作者信息

Orrego Enrique, Castaneda Carlos A, Castillo Miluska, Bernabe Luis A, Casavilca Sandro, Chakravarti Arnab, Meng Wei, Garcia-Corrochano Pamela, Villa-Robles Maria R, Zevallos Rocio, Mejia Omar, Deza Pedro, Belmar-Lopez Carolina, Ojeda Luis

机构信息

Neurosurgery Department, Instituto Nacional de Enfermedades Neoplasicas, Lima, 15038, Peru.

Research Department, Instituto Nacional de Enfermedades Neoplasicas, Lima, 15038, Peru.

出版信息

CNS Oncol. 2018 Dec 1;7(4):CNS21. doi: 10.2217/cns-2017-0037. Epub 2018 Oct 9.

DOI:10.2217/cns-2017-0037
PMID:30299157
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6331699/
Abstract

AIM

Evaluation of features related to infiltrating immune cell level in glioblastoma.

METHODS

Tumor-infiltrating lymphocytes (TILs) through H&E staining, and TILs (CD3, CD4, CD8 and CD20) and macrophage (CD68 and CD163) levels through immunohistochemistry were evaluated through digital analysis.

RESULTS

CD68 (9.1%), CD163 (2.2%), CD3 (1.6%) and CD8 (1.6%) had the highest density. Higher CD4 was associated with unmethylated MGMT (p = 0.016). Higher CD8 was associated with larger tumoral size (p = 0.027). Higher CD163 was associated with higher age (p = 0.044) and recursive partitioning analysis = 4. Women (p < 0.05), total resection (p < 0.05), MGMT-methylation (p < 0.001), radiotherapy (p < 0.001), chemotherapy (p < 0.001) and lower CD4 (p < 0.05) were associated with longer overall survival.

CONCLUSION

Macrophages are more frequent than TILs. Some subsets are associated with clinical features.

摘要

目的

评估胶质母细胞瘤中与浸润性免疫细胞水平相关的特征。

方法

通过苏木精-伊红（H&E）染色评估肿瘤浸润淋巴细胞（TILs），并通过数字分析评估免疫组化检测的TILs（CD3、CD4、CD8和CD20）及巨噬细胞（CD68和CD163）水平。

结果

CD68（9.1%）、CD163（2.2%）、CD3（1.6%）和CD8（1.6%）密度最高。较高的CD4水平与O6-甲基鸟嘌呤-DNA甲基转移酶（MGMT）未甲基化相关（p = 0.016）。较高的CD8水平与肿瘤体积较大相关（p = 0.027）。较高的CD163水平与较高年龄相关（p = 0.044）且递归分区分析=4。女性（p < 0.05）、全切除（p < 0.05）、MGMT甲基化（p < 0.001）、放疗（p < 0.001）、化疗（p < 0.001）及较低的CD4水平（p < 0.05）与总生存期较长相关。

结论

巨噬细胞比TILs更常见。一些亚群与临床特征相关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d7f0/6331699/ea42d685870b/cns-07-21-g2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d7f0/6331699/82a266f75697/cns-07-21-g1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d7f0/6331699/ea42d685870b/cns-07-21-g2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d7f0/6331699/82a266f75697/cns-07-21-g1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d7f0/6331699/ea42d685870b/cns-07-21-g2.jpg

相似文献

1
Distribution of tumor-infiltrating immune cells in glioblastoma.胶质母细胞瘤中肿瘤浸润免疫细胞的分布
CNS Oncol. 2018 Dec 1;7(4):CNS21. doi: 10.2217/cns-2017-0037. Epub 2018 Oct 9.
2
Analysis of immunobiologic markers in primary and recurrent glioblastoma.分析原发性和复发性脑胶质瘤的免疫生物学标志物。
J Neurooncol. 2018 Apr;137(2):249-257. doi: 10.1007/s11060-017-2732-1. Epub 2018 Jan 4.
3
Changes of the O6-methylguanine-DNA methyltransferase promoter methylation and MGMT protein expression after adjuvant treatment in glioblastoma.胶质母细胞瘤辅助治疗后 O6-甲基鸟嘌呤-DNA 甲基转移酶启动子甲基化和 MGMT 蛋白表达的变化。
Oncol Rep. 2010 May;23(5):1269-76. doi: 10.3892/or_00000760.
4
The correlation and prognostic significance of MGMT promoter methylation and MGMT protein in glioblastomas.胶质母细胞瘤中MGMT启动子甲基化与MGMT蛋白的相关性及预后意义
Neurosurgery. 2009 Nov;65(5):866-75; discussion 875. doi: 10.1227/01.NEU.0000357325.90347.A1.
5
MGMT promoter methylation status as a prognostic factor for the outcome of gamma knife radiosurgery for recurrent glioblastoma.MGMT启动子甲基化状态作为复发性胶质母细胞瘤伽玛刀放射外科治疗结果的预后因素。
J Neurooncol. 2017 Jul;133(3):615-622. doi: 10.1007/s11060-017-2478-9. Epub 2017 May 23.
6
Is MGMT promoter methylation to be considered in the decision making for recurrent surgery in glioblastoma patients?胶质母细胞瘤患者复发手术决策时是否应考虑MGMT启动子甲基化？
Clin Neurol Neurosurg. 2018 Apr;167:6-10. doi: 10.1016/j.clineuro.2018.02.003. Epub 2018 Feb 5.
7
A five-miRNA signature with prognostic and predictive value for MGMT promoter-methylated glioblastoma patients.一种对O6-甲基鸟嘌呤-DNA甲基转移酶（MGMT）启动子甲基化的胶质母细胞瘤患者具有预后和预测价值的五miRNA特征。
Oncotarget. 2015 Oct 6;6(30):29285-95. doi: 10.18632/oncotarget.4978.
8
MGMT methylation assessment in glioblastoma: MS-MLPA versus human methylation 450K beadchip array and immunohistochemistry.胶质母细胞瘤中MGMT甲基化评估：多重连接依赖探针扩增法（MS-MLPA）与人类甲基化450K芯片阵列及免疫组织化学比较
Clin Transl Oncol. 2016 Apr;18(4):391-7. doi: 10.1007/s12094-015-1381-0. Epub 2015 Aug 20.
9
MGMT gene promoter methylation as a potent prognostic factor in glioblastoma treated with temozolomide-based chemoradiotherapy: a single-institution study.MGMT 基因启动子甲基化作为替莫唑胺为基础的放化疗治疗胶质母细胞瘤的一种潜在预后因素：单机构研究。
Int J Radiat Oncol Biol Phys. 2012 Nov 1;84(3):661-7. doi: 10.1016/j.ijrobp.2011.12.086. Epub 2012 Mar 11.
10
O(6)-Methylguanine DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression is correlated with progression-free survival in patients with glioblastoma.启动子超甲基化和免疫组织化学表达的 O(6)-甲基鸟嘌呤 DNA 甲基转移酶与胶质母细胞瘤患者的无进展生存期相关。
Int J Clin Oncol. 2010 Aug;15(4):352-8. doi: 10.1007/s10147-010-0065-6. Epub 2010 Mar 16.

引用本文的文献

1
Unraveling Glioblastoma Heterogeneity: Advancing Immunological Insights and Therapeutic Innovations.解析胶质母细胞瘤异质性：推进免疫学见解与治疗创新
Brain Sci. 2025 Aug 2;15(8):833. doi: 10.3390/brainsci15080833.
2
5-ALA Assisted Surgery of Human Glioblastoma Samples Reveals an Enrichment of T Cells Expressing PD-1 and CD103 in the Intermediate and Marginal Layers.5-氨基乙酰丙酸辅助的人胶质母细胞瘤样本手术揭示了在中间层和边缘层中表达程序性死亡受体1（PD-1）和整合素αE（CD103）的T细胞富集。
Eur J Immunol. 2025 Jun;55(6):e51681. doi: 10.1002/eji.202451681.
3
Tumor cell-derived spermidine promotes a protumorigenic immune microenvironment in glioblastoma via CD8+ T cell inhibition.

本文引用的文献

1
Immune classifications with cytotoxic CD8 and Th17 infiltrates are predictors of clinical prognosis in glioblastoma.具有细胞毒性CD8和Th17浸润的免疫分类是胶质母细胞瘤临床预后的预测指标。
Oncoimmunology. 2017 Apr 28;6(6):e1321186. doi: 10.1080/2162402X.2017.1321186. eCollection 2017.
2
Advances in Experimental Targeted Therapy and Immunotherapy for Patients with Glioblastoma Multiforme.多形性胶质母细胞瘤患者实验性靶向治疗和免疫治疗的进展
Anticancer Res. 2017 Jan;37(1):21-33. doi: 10.21873/anticanres.11285.
3
Increased proportion of FoxP3+ regulatory T cells in tumor infiltrating lymphocytes is associated with tumor recurrence and reduced survival in patients with glioblastoma.
肿瘤细胞衍生的亚精胺通过抑制CD8 + T细胞促进胶质母细胞瘤中的促肿瘤免疫微环境。
J Clin Invest. 2024 Nov 19;135(2):e177824. doi: 10.1172/JCI177824.
4
Immune checkpoint pathways in glioblastoma: a diverse and evolving landscape.胶质母细胞瘤中的免疫检查点途径：一个多样化且不断发展的领域。
Front Immunol. 2024 Sep 13;15:1424396. doi: 10.3389/fimmu.2024.1424396. eCollection 2024.
5
Targeting NKG2D ligands in glioblastoma with a bispecific T-cell engager is augmented with conventional therapy and enhances oncolytic virotherapy of glioma stem-like cells.双特异性 T 细胞衔接器靶向胶质母细胞瘤中的 NKG2D 配体，与常规疗法联合增强胶质母细胞瘤干细胞样细胞的溶瘤病毒治疗。
J Immunother Cancer. 2024 May 9;12(5):e008460. doi: 10.1136/jitc-2023-008460.
6
Systemic and local immunosuppression in glioblastoma and its prognostic significance.脑胶质瘤的全身和局部免疫抑制及其预后意义。
Front Immunol. 2024 Feb 28;15:1326753. doi: 10.3389/fimmu.2024.1326753. eCollection 2024.
7
Immune Escape in Glioblastoma: Mechanisms of Action and Implications for Immune Checkpoint Inhibitors and CAR T-Cell Therapy.胶质母细胞瘤中的免疫逃逸：作用机制及其对免疫检查点抑制剂和嵌合抗原受体T细胞疗法的影响
Biology (Basel). 2023 Dec 15;12(12):1528. doi: 10.3390/biology12121528.
8
Development of a human glioblastoma model using humanized DRAG mice for immunotherapy.使用人源化DRAG小鼠开发用于免疫治疗的人胶质母细胞瘤模型。
Antib Ther. 2023 Oct 4;6(4):253-264. doi: 10.1093/abt/tbad021. eCollection 2023 Oct.
9
Immuno markers in newly diagnosed glioblastoma patients underwent Stupp protocol after neurosurgery: a retrospective series.新诊断的胶质母细胞瘤患者在神经外科手术后接受 Stupp 方案治疗的免疫标志物：一项回顾性系列研究。
J Neurooncol. 2023 Aug;164(1):55-64. doi: 10.1007/s11060-023-04357-9. Epub 2023 Aug 16.
10
Development and validation of cuproptosis molecular subtype-related signature for predicting immune prognostic characterization in gliomas.铜死亡分子亚型相关特征的建立和验证，用于预测脑胶质瘤的免疫预后特征。
J Cancer Res Clin Oncol. 2023 Oct;149(13):11499-11515. doi: 10.1007/s00432-023-05021-5. Epub 2023 Jul 1.
胶质母细胞瘤患者肿瘤浸润淋巴细胞中FoxP3 +调节性T细胞比例增加与肿瘤复发及生存期缩短相关。
Cancer Immunol Immunother. 2015 Apr;64(4):419-27. doi: 10.1007/s00262-014-1651-7. Epub 2015 Jan 3.
4
Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma.胶质母细胞瘤中程序性死亡配体1的表达与肿瘤浸润淋巴细胞
Neuro Oncol. 2015 Aug;17(8):1064-75. doi: 10.1093/neuonc/nou307. Epub 2014 Oct 29.
5
The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014.2014年国际肿瘤浸润淋巴细胞（TILs）工作组对乳腺癌中肿瘤浸润淋巴细胞的评估建议
Ann Oncol. 2015 Feb;26(2):259-71. doi: 10.1093/annonc/mdu450. Epub 2014 Sep 11.
6
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies.《流行病学观察研究报告的强化（STROBE）声明：观察研究报告指南》。
Int J Surg. 2014 Dec;12(12):1495-9. doi: 10.1016/j.ijsu.2014.07.013. Epub 2014 Jul 18.
7
Tumour-infiltrating CD4(+) and CD8(+) lymphocytes as predictors of clinical outcome in glioma.肿瘤浸润 CD4(+)和 CD8(+)淋巴细胞作为预测胶质瘤临床结局的指标。
Br J Cancer. 2014 May 13;110(10):2560-8. doi: 10.1038/bjc.2014.162. Epub 2014 Apr 1.
8
Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.贝伐珠单抗联合放疗-替莫唑胺治疗新诊断的胶质母细胞瘤。
N Engl J Med. 2014 Feb 20;370(8):709-22. doi: 10.1056/NEJMoa1308345.
9
A randomized trial of bevacizumab for newly diagnosed glioblastoma.贝伐珠单抗治疗新诊断的胶质母细胞瘤的随机试验。
N Engl J Med. 2014 Feb 20;370(8):699-708. doi: 10.1056/NEJMoa1308573.
10
The prognostic value of Foxp3+ tumor-infiltrating lymphocytes in patients with glioblastoma.胶质母细胞瘤患者中Foxp3+肿瘤浸润淋巴细胞的预后价值
J Neurooncol. 2014 Jan;116(2):251-9. doi: 10.1007/s11060-013-1314-0. Epub 2013 Nov 26.